Matches in SemOpenAlex for { <https://semopenalex.org/work/W3081191851> ?p ?o ?g. }
Showing items 1 to 92 of
92
with 100 items per page.
- W3081191851 endingPage "875" @default.
- W3081191851 startingPage "868" @default.
- W3081191851 abstract "Abstract Immune checkpoint inhibitors (CPIs) have radically changed outcomes for patients diagnosed with metastatic melanoma globally in the last 10 years, based on evidence of overall survival (OS) benefits generated from international randomised controlled trials (RCTs). Since RCTs do not always reflect real‐world prescribing, we interrogated established national databases to track prescribing of CPIs approved for first line treatment of metastatic melanoma patients in England since 2014 and determined patient outcomes associated with OS, as well as treatment‐related toxicity. Between April 2014 and March 2018, 5465 melanoma patients were diagnosed and treated with systemic anticancer therapy (SACT), 2322 of which received first‐line CPIs. There was good 3‐year OS concordance with RCT outcomes for ipilimumab (32%), ipinivo (56%) and nivolumab (51%), but OS was lower than expected for pembrolizumab (40%). Comparing patients prescribed ipinivo with those prescribed pembrolizumab, ipinivo‐treated patients were younger (88% vs 49% patients <70 years, P < .001) and fitter (60% vs 38% patients with Eastern Cooperative Oncology Group [ECOG] performance status 0, P < .0001). Emergency hospital admission rates from the earliest and last treatment dates were higher for patients prescribed ipinivo (37% and 55%) compared to those prescribed pembrolizumab (17% and 29%). The 30‐day mortality rates favoured ipinivo patients (3.8% ipinivo, 9.1% pembrolizumab, P < .0001) and likely reflected marked differences in median treatment durations: 63 (range 7‐440) days for ipinivo and 192 (range 5‐943) days for pembrolizumab. The dominant treatment‐related condition linked to hospital admission was colitis, recorded for 25% of patients prescribed ipinivo compared to 4% of patients prescribed pembrolizumab. Our population data has demonstrated that RCT outcomes can be achieved in routine care settings with careful patient selection." @default.
- W3081191851 created "2020-09-01" @default.
- W3081191851 creator A5002050944 @default.
- W3081191851 creator A5010263170 @default.
- W3081191851 creator A5037045438 @default.
- W3081191851 creator A5043000162 @default.
- W3081191851 creator A5045553940 @default.
- W3081191851 creator A5079727866 @default.
- W3081191851 creator A5083681824 @default.
- W3081191851 date "2020-09-12" @default.
- W3081191851 modified "2023-10-16" @default.
- W3081191851 title "Metastatic melanoma patient outcomes since introduction of immune checkpoint inhibitors in England between 2014 and 2018" @default.
- W3081191851 cites W2037489171 @default.
- W3081191851 cites W2055557358 @default.
- W3081191851 cites W2120729896 @default.
- W3081191851 cites W2123363005 @default.
- W3081191851 cites W2128035403 @default.
- W3081191851 cites W2152897456 @default.
- W3081191851 cites W2588698239 @default.
- W3081191851 cites W2736166064 @default.
- W3081191851 cites W2753432434 @default.
- W3081191851 cites W2901619788 @default.
- W3081191851 cites W2940683302 @default.
- W3081191851 cites W2963476376 @default.
- W3081191851 cites W2963698953 @default.
- W3081191851 cites W3043703771 @default.
- W3081191851 doi "https://doi.org/10.1002/ijc.33266" @default.
- W3081191851 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7821238" @default.
- W3081191851 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32838478" @default.
- W3081191851 hasPublicationYear "2020" @default.
- W3081191851 type Work @default.
- W3081191851 sameAs 3081191851 @default.
- W3081191851 citedByCount "11" @default.
- W3081191851 countsByYear W30811918512020 @default.
- W3081191851 countsByYear W30811918512021 @default.
- W3081191851 countsByYear W30811918512022 @default.
- W3081191851 countsByYear W30811918512023 @default.
- W3081191851 crossrefType "journal-article" @default.
- W3081191851 hasAuthorship W3081191851A5002050944 @default.
- W3081191851 hasAuthorship W3081191851A5010263170 @default.
- W3081191851 hasAuthorship W3081191851A5037045438 @default.
- W3081191851 hasAuthorship W3081191851A5043000162 @default.
- W3081191851 hasAuthorship W3081191851A5045553940 @default.
- W3081191851 hasAuthorship W3081191851A5079727866 @default.
- W3081191851 hasAuthorship W3081191851A5083681824 @default.
- W3081191851 hasBestOaLocation W30811918511 @default.
- W3081191851 hasConcept C121608353 @default.
- W3081191851 hasConcept C126322002 @default.
- W3081191851 hasConcept C143998085 @default.
- W3081191851 hasConcept C160798450 @default.
- W3081191851 hasConcept C2777658100 @default.
- W3081191851 hasConcept C2777701055 @default.
- W3081191851 hasConcept C2780030458 @default.
- W3081191851 hasConcept C2780057760 @default.
- W3081191851 hasConcept C2781433595 @default.
- W3081191851 hasConcept C2994587330 @default.
- W3081191851 hasConcept C502942594 @default.
- W3081191851 hasConcept C71924100 @default.
- W3081191851 hasConceptScore W3081191851C121608353 @default.
- W3081191851 hasConceptScore W3081191851C126322002 @default.
- W3081191851 hasConceptScore W3081191851C143998085 @default.
- W3081191851 hasConceptScore W3081191851C160798450 @default.
- W3081191851 hasConceptScore W3081191851C2777658100 @default.
- W3081191851 hasConceptScore W3081191851C2777701055 @default.
- W3081191851 hasConceptScore W3081191851C2780030458 @default.
- W3081191851 hasConceptScore W3081191851C2780057760 @default.
- W3081191851 hasConceptScore W3081191851C2781433595 @default.
- W3081191851 hasConceptScore W3081191851C2994587330 @default.
- W3081191851 hasConceptScore W3081191851C502942594 @default.
- W3081191851 hasConceptScore W3081191851C71924100 @default.
- W3081191851 hasIssue "4" @default.
- W3081191851 hasLocation W30811918511 @default.
- W3081191851 hasLocation W30811918512 @default.
- W3081191851 hasOpenAccess W3081191851 @default.
- W3081191851 hasPrimaryLocation W30811918511 @default.
- W3081191851 hasRelatedWork W2155654588 @default.
- W3081191851 hasRelatedWork W2773756552 @default.
- W3081191851 hasRelatedWork W2888298425 @default.
- W3081191851 hasRelatedWork W2932851203 @default.
- W3081191851 hasRelatedWork W2963333658 @default.
- W3081191851 hasRelatedWork W3094969222 @default.
- W3081191851 hasRelatedWork W3118553317 @default.
- W3081191851 hasRelatedWork W3185931698 @default.
- W3081191851 hasRelatedWork W4206663608 @default.
- W3081191851 hasRelatedWork W4318473990 @default.
- W3081191851 hasVolume "148" @default.
- W3081191851 isParatext "false" @default.
- W3081191851 isRetracted "false" @default.
- W3081191851 magId "3081191851" @default.
- W3081191851 workType "article" @default.